Free tool
FAERS Monitor: Datscan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022454 or its brand name (Datscan, Ioflupane I-123). Reports on generic versions are filed under their own applications.
Reports
541
Serious
90
17% of reports
Hospitalization
17
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event263
- radioisotope scan abnormal148
- drug ineffective128
- injection site pain59
- drug interaction49
- parkinsonism26
- burning sensation24
- false positive radioisotope investigation result16
- dopamine transporter scintigraphy abnormal12
- nausea12
- product quality issue11
- headache10
- malaise10
- dizziness9
- pain9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 7 |
| 2015 | 16 |
| 2016 | 27 |
| 2017 | 74 |
| 2018 | 63 |
| 2019 | 55 |
| 2020 | 44 |
| 2021 | 37 |
| 2022 | 32 |
| 2023 | 37 |
| 2024 | 72 |
| 2025 | 50 |
| 2026 | 25 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,618 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| false positive radioisotope investigation resultSignal | 16 | 103776.3 | 40762.0 | 424,973 |
| dopamine transporter scintigraphy abnormalSignal | 12 | 22237.8 | 10996.1 | 155,945 |
| radioisotope scan abnormalSignal | 148 | 10303.4 | 8776.4 | 1,197,358 |
| parkinsonismSignal | 26 | 103.9 | 71.4 | 2,543 |
| no adverse eventSignal | 263 | 56.5 | 51.8 | 14,390 |
| burning sensationSignal | 24 | 13.3 | 9.0 | 262 |
| drug interactionSignal | 49 | 12.0 | 9.2 | 487 |
| injection site painSignal | 59 | 7.5 | 5.9 | 329 |
| drug ineffectiveSignal | 128 | 3.8 | 3.2 | 276 |
| product quality issueSignal | 11 | 3.1 | 1.8 | 14 |
| malaise | 10 | 0.9 | 0.5 | 0 |
| dizziness | 9 | 0.7 | 0.4 | 1 |
| headache | 10 | 0.6 | 0.3 | 2 |
| nausea | 12 | 0.6 | 0.3 | 3 |
| pain | 9 | 0.6 | 0.3 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.